<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00671099</url>
  </required_header>
  <id_info>
    <org_study_id>NDMC-TPOP-02</org_study_id>
    <nct_id>NCT00671099</nct_id>
  </id_info>
  <brief_title>Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study</brief_title>
  <official_title>Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Science and Technology Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toyama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiba University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Science and Technology Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of Polyunsaturated Fatty Acid
      for the prevention of Posttraumatic Stress Disorder (PTSD) in patients with accidental
      injuries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accidental injuries, mostly motor vehicle accident, in civilian population are frequent
      events.For instance, nearly one-third of injured patients appear to develop trauma-related
      psychiatric illness and the major diagnoses are post-traumatic stress disorder (PTSD) and
      depressive disorder.Omega-3 Polyunsaturated Fatty Acid (Omega-3 PUFA) has some evidence of
      efficacy of treatment in patients with anxiety and mood disorders, but no evidence of
      preventing anxiety and mood disorders that occur subsequent to accidental injuries.We
      evaluate efficacy and safety of Omega-3 PUFA for the secondary prevention of Posttraumatic
      Stress Disorder (PTSD) and related psychiatric illness in patients with accidental injury
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total score of Clinician-Administrated PTSD Scale</measure>
    <time_frame>Three month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of diagnosis of PTSD (including partial PTSD)</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score of Montgomery Asberg Depression Rating Scale (MADRAS)</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of depression evaluated by Mini-International Neuropsychiatric Interview (MINI)</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autonomic response measured before, during and after script driven imagery and acoustic stimulation</measure>
    <time_frame>Three month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of Impact of Event Scale revised (IES-R)</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of Hospital Anxiety and Depression scale (HADS)</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of health related Quality of Life scale, SF-36</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of Conner-Davidson Resilience Scale (CD-RISC)</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain-derived neurotrophic factor (BDNF) in serum</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of leave taken from the time of injury</measure>
    <time_frame>Three month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Buss-Perry Aggression Questionnaire (BAQ)</measure>
    <time_frame>Three month, one month, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score of Clinician-Administrated PTSD Scale (CAPS)</measure>
    <time_frame>One month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DHEA: dehydroepiandrosterone</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NPY: neuropeptide Y</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1 beta: interleukin 1 beta</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6: interleukin 6</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF alpha: tumor necrosis factor alpha</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-serine</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L-serine</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DL-serine</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activin</measure>
    <time_frame>Three month, one month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Trauma</condition>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement: Omega-3 Polyunsaturated Fatty Acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3 Polyunsaturated Fatty Acid</intervention_name>
    <description>A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 plus years

          2. A native Japanese speaking ability

          3. Possibility to contact patients with injury in 240 hours, and dosing in oral use

          4. Physical and metal status to possible understands scope and contents in the trial and
             gets informed consent

        Exclusion Criteria:

          1. Clearly irretrievable acute brain parenchyma damage and subdural or subarachnoidal
             bleeding detected by computed tomography and/or magnetic resonance imaging

          2. Cognitive impairment: Mini Mental State Examination &lt; 24

          3. Heavy drinker or 100IU/L ≦ γGTP in administration

          4. Heavy smoker (over 40 cigarettes per day)

          5. History and current suspicion in diagnosis of psychosis and bipolar I disorder

          6. Suspicion in diagnosis of alcoholic, substance-related disorder and eating disorder

          7. Existence of marked serious symptoms such as suicidal ideation, self-harm behavior,
             dissociation, status of need rapidly psychiatric treatment

          8. Use of anti-epilepsy drug, lithium, ethyl icosapentate and anti-coagulant drug (for
             example, aspirin, warfarin, etc) within 3 month at regular intervals

          9. Use of polyunsaturated fatty acid supplement within 3 month at regular intervals

         10. Habit of eating fish over 4 times per week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yutaka Matsuoka, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Disaster Medical Center, Tachikawa, Tokyo ,Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Disaster Medical Center</name>
      <address>
        <city>Tachikawa</city>
        <state>Tokyo</state>
        <zip>1900014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Matsuoka Y, Nishi D, Yonemoto N, Hamazaki K, Matsumura K, Noguchi H, Hashimoto K, Hamazaki T. Tachikawa project for prevention of posttraumatic stress disorder with polyunsaturated fatty acid (TPOP): study protocol for a randomized controlled trial. BMC Psychiatry. 2013 Jan 5;13:8. doi: 10.1186/1471-244X-13-8.</citation>
    <PMID>23289548</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2008</study_first_submitted>
  <study_first_submitted_qc>May 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2008</study_first_posted>
  <last_update_submitted>January 20, 2014</last_update_submitted>
  <last_update_submitted_qc>January 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Japan Science and Technology Agency</investigator_affiliation>
    <investigator_full_name>Yutaka Matsuoka</investigator_full_name>
    <investigator_title>Psychiatrist</investigator_title>
  </responsible_party>
  <keyword>Patients</keyword>
  <keyword>with high-energy</keyword>
  <keyword>admitted</keyword>
  <keyword>intensive care unit</keyword>
  <keyword>motor vehicle accident</keyword>
  <keyword>falling from height</keyword>
  <keyword>other accident</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

